ALK and non-small cell lung carcinoma: Of the five compounds, we validated the effect of crizotinib, an approved drug for anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), because of its unreported bioactivity and potential for drug repurposing.